SAN FRANCISCO, CA--(Marketwired - October 29, 2015) - SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.
Included in this interview with Tandon and Albany are: Aethlon Medical Inc. (
The Life Sciences Report: Given the current healthcare market, how does the future look for small-cap biotechs versus large-cap companies?
Ajay Tandon: There seems to be a pretty robust market for micro caps in the life sciences sector. We currently cover 168 companies, and about a third of the coverage universe is life sciences and biotech-focused. There is a lot of activity in this sector.
TLSR: Do any particular subsectors stand out?
Jay Albany: There's been a lot of excitement around precision immunotherapy recently. It has the potential to harness the immune system in a targeted and personalized way. A lot of people believe…
Continue reading this interview: Eight Ways to Leverage the Small-Cap Biotech Bull Market: Ajay Tandon and Jay Albany of SeeThruEquity
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Aethlon Medical Inc., Cynata Therapeutics Ltd. and RestorGenex Corp. are sponsors of Streetwise Reports. Mr. Tandon and Mr. Albany had final approval of the content and are wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Tandon and Mr. Albany not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Contact Information:
Jim Patrick